IPSC compared with LBRX: revenue, margins and what each company keeps, and the suppliers and customers both name

IPSCCentury Therapeutics, Inc.

Mkt capRevenueRevenue

LBRXLB Pharmaceuticals Inc

Mkt capRevenueRevenue

Compare

IPSCCentury Therapeutics, Inc.

LBRXLB Pharmaceuticals Inc

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

IPSC1 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±29.8%▼−4.85%×0.16

LBRX

0 of 1at or beyond implied

Reportimpliedrealized× implied

Q3 FY26thin chain±13.5%▲+10.29%×0.76

Q2 FY26—▼−1.13%—

= impliedIPSC realized, solidLBRX realized, hatchedOne scale, both sides: full bar = 30%× = |realized| ÷ impliedSource: market data

May 13 '26—▲+3.79%—

Q1 FY26—▼−2.81%—

IPSCCentury Therapeutics, Inc.

1.70▲+12.33%· post 1.70

Mkt cap$304.2MRevenue$109MQ1 FY25Revenue$7MFY24

LBRXLB Pharmaceuticals Inc

42.14▲+10.63%· post 41.17

ClosedNov 6 '26

Mkt cap$1.4BRevenue—Revenue—

Compare

ClosedNov 6 '26

IPSCCentury Therapeutics, Inc.

LBRXLB Pharmaceuticals Inc

1.70▲+12.33%post 1.70

Price

42.14▲+10.63%post 41.17

$304.2M

Mkt cap

$1.4B

Q1 FY25$109M

Revenue

—

FY24$7M

Revenue

—

IPSC1.70▲+12.33%vsLBRX42.14▲+10.63%ClosedNov 6 '26